RecruitingHepatocellular CarcinomaSquamous Cell Non-Small Cell Lung CancerGerm Cell Tumor
A Study of ZW251 in Participants With Advanced Solid Tumors
Eligible age
18+ yrs
Accepts
All genders
Locations
6 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
The purpose of this study is to find out if ZW251, an antibody-drug conjugate targeting glypican-3 (GPC3), is safe and can treat participants with advanced cancers, including hepatocellular carcinoma (HCC), squamous cell non-small cell lung cancer (NSCLC), or germ cell tumors (GCT).
Sponsor: Zymeworks BC Inc.
You may qualify if…
- ✓ Pathologically or cytologically confirmed diagnosis of HCC with evidence of locally advanced (unresectable, and ineligible for transplant) and/or metastatic disease. Noninvasive methods may be used to confirm diagnosis
- ✓ Pathologically or cytologically confirmed diagnosis of squamous cell NSCLC with evidence of locally advanced (unresectable) and/or metastatic disease
- ✓ Pathologically or cytologically confirmed diagnosis of GCT with evidence of yolk sac and/or choriocarcinoma predominant component and locally advanced (unresectable) and/or metastatic disease
- ✓ Measurable disease per RECIST v1.1
- ✓ Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0 or 1
- ✓ Liver function status of Child-Pugh Class A (for HCC only)
- ✓ Adequate organ function
You may not qualify if…
- ✕ Known additional malignancy that is progressing or that has required active treatment within the last year
- ✕ History of hepatic encephalopathy within the past 6 months or requirement for medications to control encephalopathy
- ✕ Participants with HCC experiencing main portal vein tumor invasion require sponsor approval for enrollment
- ✕ Known gastrointestinal bleeding within 3 months
- ✕ Acute or chronic uncontrolled renal disease, pancreatitis, or non-malignant liver disease
Where it's recruiting
California
San Francisco · Santa Monica
Kentucky
Louisville
Michigan
Grand Rapids
New Jersey
Hackensack
New York
New York
Texas
Houston · San Antonio
Source: ClinicalTrials.gov · NCT07164313 · last updated 2026-05-07